Your browser doesn't support javascript.
loading
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).
González, A; Lluch, A; Aba, E; Albanell, J; Antón, A; Álvarez, I; Ayala, F; Barnadas, A; Calvo, L; Ciruelos, E; Cortés, J; de la Haba, J; López-Vega, J M; Martínez, E; Muñoz, M; Peláez, I; Redondo, A; Rodríguez, Á; Rodríguez, C A; Ruíz, A; Llombart, A.
Afiliación
  • González A; Medical Oncology Department, MD Anderson Cancer Center, C/Arturo Soria, 270, 28033, Madrid, Spain. agonzalezm@seom.org.
  • Lluch A; Hematology and Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • Aba E; Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
  • Albanell J; Medical Oncology Department, Hospital Parc de Salut Mar, Barcelona, Spain.
  • Antón A; Medical Oncology Department, Hospital Miguel Servet, Zaragoza, Spain.
  • Álvarez I; Medical Oncology Department, Hospital Universitario Donostia, San Sebastián, Spain.
  • Ayala F; Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
  • Barnadas A; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Calvo L; Medical Oncology Department, Complejo Hospitalario Universitario de La Coruña, La Coruña, Spain.
  • Ciruelos E; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Cortés J; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • de la Haba J; Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
  • López-Vega JM; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Martínez E; Medical Oncology Department, Fundación Hospital Provincial de Castellón, Castellón, Spain.
  • Muñoz M; Medical Oncology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Peláez I; Medical Oncology Department, Hospital de Cabueñes, Gijón, Spain.
  • Redondo A; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain.
  • Rodríguez Á; Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain.
  • Rodríguez CA; Medical Oncology Department, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.
  • Ruíz A; Instituto Valenciano de Oncología, Valencia, Spain.
  • Llombart A; Medical Oncology Department, Hospital Universitario Arnau Vilanova, Lleida, Spain.
Clin Transl Oncol ; 19(5): 616-624, 2017 May.
Article en En | MEDLINE | ID: mdl-27853985
PURPOSE: To converge on an expert opinion to define aggressive disease in patients with HER2-negative mBC using a modified Delphi methodology. METHODS: A panel of 21 breast cancer experts from the Spanish Society of Medical Oncology agreed upon a survey which comprised 47 questions that were grouped into three sections: relevance for defining aggressive disease, aggressive disease criteria and therapeutic goals. Answers were rated using a 9-point Likert scale of relevance or agreement. RESULTS: Among the 88 oncologists that were invited to participate, 81 answered the first round (92%), 70 answered the second round (80%), and 67 answered the third round (76%) of the survey. There was strong agreement regarding the fact that identifying patients with aggressive disease needs to be adequately addressed to help practitioners to decide the best treatment options for patients with HER2-negative mBC. The factors that were considered to be strongly relevant to classifying patients with aggressive HER2-negative mBC were a high tumor burden, a disease-free interval of less than 12-24 months after surgery, the presence of progressive disease during adjuvant or neoadjuvant chemotherapy and having a triple-negative phenotype. The main therapeutic goals were controlling symptoms, improving quality of life and increasing the time to progression and overall survival. CONCLUSIONS: High tumor burden, time to recurrence after prior therapy and having a triple-negative phenotype were the prognostic factors for which the greatest consensus was found for identifying patients with aggressive HER2-negative mBC. Identifying patients with aggressive disease leads to different therapeutic approaches.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Oncología Médica Tipo de estudio: Guideline / Prognostic_studies Aspecto: Patient_preference Límite: Female / Humans Idioma: En Revista: Clin Transl Oncol Año: 2017 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Oncología Médica Tipo de estudio: Guideline / Prognostic_studies Aspecto: Patient_preference Límite: Female / Humans Idioma: En Revista: Clin Transl Oncol Año: 2017 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia